November 15, 2024

PHABIOC GmbH Launches Series Production of the Revolutionary SpecPlate for Pharmaceutical and Biotech Research

PHABIOC GmbH Launches Series Production of the Revolutionary SpecPlate for Pharmaceutical and Biotech Research

A new level of efficiency, precision and sustainability in UV/Vis spectroscopy

PHABIOC GmbH announces the start of mass production of its innovative SpecPlate – a multiwell plate designed specifically for the needs of pharmaceutical and biotech research. The SpecPlate sets new standards in plate-based UV/Vis spectroscopy by improving efficiency and precision while significantly reducing material consumption. This makes laboratory processes more effective and sustainable.

Technological innovation for more accurate results 

The SpecPlate features closed, stepped measurement chambers that allow measurements over a wide range of concentrations without the need for dilution. With a sample volume of only 36 µL, the measurement chambers provide a defined path length and eliminate the influence of liquid menisci or pipetting inaccuracies on the measurement result. Compatibility with popular plate readers and automated pipetting systems is particularly advantageous: The inlets of the measurement structures are arranged in the grid of a standard 96-well plate, while the measurement chambers are arranged in the grid of a 384-well plate. This allows the SpecPlate to be seamlessly integrated into established laboratory systems and processes. 

“The SpecPlate addresses the errors and limitations of the gold standard and combines its advantages. The SpecPlate is the better standard,” says Dr. Carsten Radtke, co-inventor of the SpecPlate and CSO of PHABIOC GmbH.

Sustainability and efficiency in a single product 

In comparative tests, the SpecPlate impressed not only with its precision, but also with considerable savings: 75% less laboratory consumables and a two-thirds reduction in process time. This increase in efficiency makes the SpecPlate particularly attractive to laboratories that value fast, cost-effective and sustainable processes.

Developed from cutting-edge research and collaborative partnerships

The SpecPlate was originally developed at the Karlsruhe Institute of Technology (KIT) in the research group of Prof. Jürgen Hubbuch. Together with industry partners, the SpecPlate was brought to market. PHABIOC is pleased to have found a manufacturing partner in Germany that offers short delivery and communication channels as well as the highest product quality.

Early customer feedback confirms the benefits of SpecPlate 

The SpecPlate has already received positive feedback from pilot customers, including some of the leading pharmaceutical companies:

“The integration of SpecPlate promises to significantly speed up and simplify our processes by reducing the number of steps required and enabling us to obtain more data points from the sample measurements. “*

Another customer praises the compatibility: “The use in already established instruments offers a low integration threshold into our existing workflows”.

Contact:

Dr.-Ing. Carsten Radtke 
PHABIOC GmbH 
E-mail: carsten.radtke@phabioc.com 
Fon: +49 123 45678 
Website: http://www.phabioc.com

Our latest News

discover more
Digital recording of health status

Digital recording of health status

Successful pilot project at Heidelberg University Hospital Regularly surveying patients about their health-related quality of life is a key aspect of patient-centred medicine. At Heidelberg University Hospital, a new digital system is being used for this purpose in a pilot project: patients complete online questionnaires on their own mobile devices, after which the data is […]

A mouse model for Dry Eye Disease

A mouse model for Dry Eye Disease

Experimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities. Dry eye disease, also referred […]

Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Foster City, Calif., and Munich, Germany – April 7, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead’s oncology pipeline, focused on addressing areas of high unmet need. The acquisition significantly […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp